ClinVar Miner

Submissions for variant NM_000228.3(LAMB3):c.1117C>T (p.Gln373Ter)

dbSNP: rs1057517096
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000411684 SCV000486741 pathogenic Junctional epidermolysis bullosa gravis of Herlitz 2016-08-02 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000778965 SCV000915392 likely pathogenic Junctional epidermolysis bullosa 2018-10-30 criteria provided, single submitter clinical testing The LAMB3 c.1117C>T (p.Gln373Ter) variant is a stop-gained variant predicted to result in premature termination of the protein. It has been reported in two studies in which is found in a compound heterozygous state with the recurrent LAMB3 variant, p.Arg635Ter, in three affected individuals. All three individuals presented with a severe, neonatal-lethal form of junctional epidermolysis bullosa known as Herlitz disease or H-JEB. (Muhle et al. 2005; Tolar et al. 2013) Control data are unavailable for this variant, which is reported at a frequency of 0.000009 in the European (non-Finnish) population of the Genome Aggregation Database but this is based on one allele in a region of good sequence coverage, so the variant is presumed to be rare. Skin biopsy studies showed reduced laminin-5 expression in two probands (Muhle et al. 2005) and absence of laminin B3 chain at the dermal epidermal junction in one proband (Tolar et al. 2013). Based on the evidence, the variant is classified as likely pathogenic for junctional epidermolysis bullosa. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV001383403 SCV001582537 pathogenic not provided 2023-04-17 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 371216). This premature translational stop signal has been observed in individual(s) with junctional epidermolysis bullosa (PMID: 11023379, 25950805, 28830826). This variant is present in population databases (no rsID available, gnomAD 0.0009%). This sequence change creates a premature translational stop signal (p.Gln373*) in the LAMB3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in LAMB3 are known to be pathogenic (PMID: 11023379, 16473856).
Revvity Omics, Revvity RCV001383403 SCV002023900 pathogenic not provided 2022-02-11 criteria provided, single submitter clinical testing
GeneDx RCV001383403 SCV002757035 pathogenic not provided 2022-11-17 criteria provided, single submitter clinical testing Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 22931927, 11023379, 25950805, 15538630, 28830826)
Pars Genome Lab RCV003114525 SCV003798447 pathogenic Junctional epidermolysis bullosa, non-Herlitz type criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.